Genomic Health begins validation study of colon cancer assay
Utilizing more than 1,200 patient samples from the Quasar trial, the validation study will use prospectively defined endpoints to assess the clinical utility of the Oncotype DX colon
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.